Loading…
Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis
To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients. The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The...
Saved in:
| Published in: | Journal of the Pakistan Medical Association 2024-06, Vol.74 (6 (Supple-6)), p.S34-S40 |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | |
| container_end_page | S40 |
| container_issue | 6 (Supple-6) |
| container_start_page | S34 |
| container_title | Journal of the Pakistan Medical Association |
| container_volume | 74 |
| creator | Harsoyo, Primasitha Maharani Hermawan, Hanestya Oky Hariftyani, Arisvia Sukma Shabrina, Farah Aisha Paramitha, Anisya Dinda Desita, Saskia Ratna Oktaviono, Yudi Her |
| description | To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients.
The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4.
Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p |
| doi_str_mv | 10.47391/JPMA.S6-ACSA-07 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3082305664</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3082305664</sourcerecordid><originalsourceid>FETCH-LOGICAL-c182t-b43e3a66c3b8b11017feaadd7bf6b2e5d54243eaff7c7d5c8be0ecce870bd8283</originalsourceid><addsrcrecordid>eNpNkE1LAzEQhoMotlbvnmSPXrZONt1N6m0pflJRqJ5Dkp0tKftRN1ml_npTW8XTzMDzvgwPIecUxhPOpvTq8eUpHy-yOJ8t8hj4ARkCMIinU5Ec_tsH5MS5FUCSpQDHZMCmQAVlfEhWebO07RIbdNZFbe9NW2NYyqhGX7ZdbZuo97ayX8rbtonCWVil0QeoxqqyvnfXkYrcxnmsA2OiDj8sfkaqKbYdKlaNqjah_ZQclapyeLafI_J2e_M6u4_nz3cPs3weGyoSH-sJQ6ayzDAtNKVAeYlKFQXXZaYTTIt0kgRElSU3vEiN0AhoDAoOuhCJYCNyuetdd-17j87L2joTflUNtr2TDETCIM2ySUBhh5quda7DUq47W6tuIynIH8Nya1guMrk1LIGHyMW-vdc1Fn-BX6XsGym3eww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3082305664</pqid></control><display><type>article</type><title>Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis</title><source>DOAJ Directory of Open Access Journals</source><creator>Harsoyo, Primasitha Maharani ; Hermawan, Hanestya Oky ; Hariftyani, Arisvia Sukma ; Shabrina, Farah Aisha ; Paramitha, Anisya Dinda ; Desita, Saskia Ratna ; Oktaviono, Yudi Her</creator><creatorcontrib>Harsoyo, Primasitha Maharani ; Hermawan, Hanestya Oky ; Hariftyani, Arisvia Sukma ; Shabrina, Farah Aisha ; Paramitha, Anisya Dinda ; Desita, Saskia Ratna ; Oktaviono, Yudi Her</creatorcontrib><description>To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients.
The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4.
Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p<0.00001), intercellular adhesion molecule-1 (p=0.0003), soluble endothelial-selectin (p=0.007), and tissue plasminogen activator (p<0.00001) showed significantly lower levels after metformin treatment using the random effect methods.
Metformin was found to have an additional effect of endothelial function improvement.</description><identifier>ISSN: 0030-9982</identifier><identifier>EISSN: 0030-9982</identifier><identifier>DOI: 10.47391/JPMA.S6-ACSA-07</identifier><identifier>PMID: 39018137</identifier><language>eng</language><publisher>Pakistan</publisher><subject>Angiogenesis ; Diabetes Mellitus, Type 2 - drug therapy ; E-Selectin - blood ; Humans ; Hypoglycemic Agents - therapeutic use ; Intercellular Adhesion Molecule-1 - blood ; Intercellular Adhesion Molecule-1 - metabolism ; Metformin - therapeutic use ; Plasminogen Activator Inhibitor 1 - blood ; Plasminogen Activator Inhibitor 1 - metabolism ; Tissue Plasminogen Activator ; Vascular Cell Adhesion Molecule-1 - blood ; Vascular Endothelial Growth Factor A - blood ; Vascular Endothelial Growth Factor A - metabolism ; von Willebrand Factor - metabolism</subject><ispartof>Journal of the Pakistan Medical Association, 2024-06, Vol.74 (6 (Supple-6)), p.S34-S40</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39018137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Harsoyo, Primasitha Maharani</creatorcontrib><creatorcontrib>Hermawan, Hanestya Oky</creatorcontrib><creatorcontrib>Hariftyani, Arisvia Sukma</creatorcontrib><creatorcontrib>Shabrina, Farah Aisha</creatorcontrib><creatorcontrib>Paramitha, Anisya Dinda</creatorcontrib><creatorcontrib>Desita, Saskia Ratna</creatorcontrib><creatorcontrib>Oktaviono, Yudi Her</creatorcontrib><title>Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis</title><title>Journal of the Pakistan Medical Association</title><addtitle>J Pak Med Assoc</addtitle><description>To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients.
The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4.
Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p<0.00001), intercellular adhesion molecule-1 (p=0.0003), soluble endothelial-selectin (p=0.007), and tissue plasminogen activator (p<0.00001) showed significantly lower levels after metformin treatment using the random effect methods.
Metformin was found to have an additional effect of endothelial function improvement.</description><subject>Angiogenesis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>E-Selectin - blood</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Intercellular Adhesion Molecule-1 - blood</subject><subject>Intercellular Adhesion Molecule-1 - metabolism</subject><subject>Metformin - therapeutic use</subject><subject>Plasminogen Activator Inhibitor 1 - blood</subject><subject>Plasminogen Activator Inhibitor 1 - metabolism</subject><subject>Tissue Plasminogen Activator</subject><subject>Vascular Cell Adhesion Molecule-1 - blood</subject><subject>Vascular Endothelial Growth Factor A - blood</subject><subject>Vascular Endothelial Growth Factor A - metabolism</subject><subject>von Willebrand Factor - metabolism</subject><issn>0030-9982</issn><issn>0030-9982</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkE1LAzEQhoMotlbvnmSPXrZONt1N6m0pflJRqJ5Dkp0tKftRN1ml_npTW8XTzMDzvgwPIecUxhPOpvTq8eUpHy-yOJ8t8hj4ARkCMIinU5Ec_tsH5MS5FUCSpQDHZMCmQAVlfEhWebO07RIbdNZFbe9NW2NYyqhGX7ZdbZuo97ayX8rbtonCWVil0QeoxqqyvnfXkYrcxnmsA2OiDj8sfkaqKbYdKlaNqjah_ZQclapyeLafI_J2e_M6u4_nz3cPs3weGyoSH-sJQ6ayzDAtNKVAeYlKFQXXZaYTTIt0kgRElSU3vEiN0AhoDAoOuhCJYCNyuetdd-17j87L2joTflUNtr2TDETCIM2ySUBhh5quda7DUq47W6tuIynIH8Nya1guMrk1LIGHyMW-vdc1Fn-BX6XsGym3eww</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Harsoyo, Primasitha Maharani</creator><creator>Hermawan, Hanestya Oky</creator><creator>Hariftyani, Arisvia Sukma</creator><creator>Shabrina, Farah Aisha</creator><creator>Paramitha, Anisya Dinda</creator><creator>Desita, Saskia Ratna</creator><creator>Oktaviono, Yudi Her</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240601</creationdate><title>Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis</title><author>Harsoyo, Primasitha Maharani ; Hermawan, Hanestya Oky ; Hariftyani, Arisvia Sukma ; Shabrina, Farah Aisha ; Paramitha, Anisya Dinda ; Desita, Saskia Ratna ; Oktaviono, Yudi Her</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c182t-b43e3a66c3b8b11017feaadd7bf6b2e5d54243eaff7c7d5c8be0ecce870bd8283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Angiogenesis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>E-Selectin - blood</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Intercellular Adhesion Molecule-1 - blood</topic><topic>Intercellular Adhesion Molecule-1 - metabolism</topic><topic>Metformin - therapeutic use</topic><topic>Plasminogen Activator Inhibitor 1 - blood</topic><topic>Plasminogen Activator Inhibitor 1 - metabolism</topic><topic>Tissue Plasminogen Activator</topic><topic>Vascular Cell Adhesion Molecule-1 - blood</topic><topic>Vascular Endothelial Growth Factor A - blood</topic><topic>Vascular Endothelial Growth Factor A - metabolism</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Harsoyo, Primasitha Maharani</creatorcontrib><creatorcontrib>Hermawan, Hanestya Oky</creatorcontrib><creatorcontrib>Hariftyani, Arisvia Sukma</creatorcontrib><creatorcontrib>Shabrina, Farah Aisha</creatorcontrib><creatorcontrib>Paramitha, Anisya Dinda</creatorcontrib><creatorcontrib>Desita, Saskia Ratna</creatorcontrib><creatorcontrib>Oktaviono, Yudi Her</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the Pakistan Medical Association</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harsoyo, Primasitha Maharani</au><au>Hermawan, Hanestya Oky</au><au>Hariftyani, Arisvia Sukma</au><au>Shabrina, Farah Aisha</au><au>Paramitha, Anisya Dinda</au><au>Desita, Saskia Ratna</au><au>Oktaviono, Yudi Her</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis</atitle><jtitle>Journal of the Pakistan Medical Association</jtitle><addtitle>J Pak Med Assoc</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>74</volume><issue>6 (Supple-6)</issue><spage>S34</spage><epage>S40</epage><pages>S34-S40</pages><issn>0030-9982</issn><eissn>0030-9982</eissn><abstract>To review relevant literature regarding the role of metformin in angiogenesis among diabetic patients.
The systematic review and meta-analysis conducted from May to September 2022, and comprised search on Medline, ScienceDirect, ProQuest, Web of Science, EBSCOhost and Cochrane Library databases. The studies included were published in the English language and were human studies having angiogenesis endothelial markers as the outcomes of interest among patients of type 2 diabetes mellitus undergoing metformin therapy. Endothelial markers, including vascular endothelial growth factor, von-Willebrand-factor, plasminogen activator inhibitor-1, soluble vascular adhesion molecule- 1, intercellular adhesion molecule-1, soluble endothelialselectin, tissue plasminogen activator, urinary albumin excretion, platelet endothelial cell adhesion molecule-1 and thrombin-activatable fibrinolysis inhibitor, were assessed as angiogenesis outcomes. Data was statistically analysed using Review Manager 5.4.
Of the 413 studies identified, 8(1.9%) were included; 5(62.5%) randomised control trials, 2(25.0%) cross-sectional, and 1(12.5%) cohort studies, with overall 1199 patients. Among the outcomes, von-Willebrandfactor (p=0.01), soluble vascular adhesion molecule-1 (p<0.00001), intercellular adhesion molecule-1 (p=0.0003), soluble endothelial-selectin (p=0.007), and tissue plasminogen activator (p<0.00001) showed significantly lower levels after metformin treatment using the random effect methods.
Metformin was found to have an additional effect of endothelial function improvement.</abstract><cop>Pakistan</cop><pmid>39018137</pmid><doi>10.47391/JPMA.S6-ACSA-07</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-9982 |
| ispartof | Journal of the Pakistan Medical Association, 2024-06, Vol.74 (6 (Supple-6)), p.S34-S40 |
| issn | 0030-9982 0030-9982 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3082305664 |
| source | DOAJ Directory of Open Access Journals |
| subjects | Angiogenesis Diabetes Mellitus, Type 2 - drug therapy E-Selectin - blood Humans Hypoglycemic Agents - therapeutic use Intercellular Adhesion Molecule-1 - blood Intercellular Adhesion Molecule-1 - metabolism Metformin - therapeutic use Plasminogen Activator Inhibitor 1 - blood Plasminogen Activator Inhibitor 1 - metabolism Tissue Plasminogen Activator Vascular Cell Adhesion Molecule-1 - blood Vascular Endothelial Growth Factor A - blood Vascular Endothelial Growth Factor A - metabolism von Willebrand Factor - metabolism |
| title | Angiogenesis outcomes of metformin utilization in diabetes mellitus: a systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A56%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Angiogenesis%20outcomes%20of%20metformin%20utilization%20in%20diabetes%20mellitus:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Journal%20of%20the%20Pakistan%20Medical%20Association&rft.au=Harsoyo,%20Primasitha%20Maharani&rft.date=2024-06-01&rft.volume=74&rft.issue=6%20(Supple-6)&rft.spage=S34&rft.epage=S40&rft.pages=S34-S40&rft.issn=0030-9982&rft.eissn=0030-9982&rft_id=info:doi/10.47391/JPMA.S6-ACSA-07&rft_dat=%3Cproquest_cross%3E3082305664%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c182t-b43e3a66c3b8b11017feaadd7bf6b2e5d54243eaff7c7d5c8be0ecce870bd8283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3082305664&rft_id=info:pmid/39018137&rfr_iscdi=true |